Bexion, UCCI announces dosing of first patient in BXQ-350 trial

Bexion Pharmaceuticals LLC and the University of Cincinnati Cancer Institute (UCCI) this week announced that the first patient in the Phase I BXQ-350 trial has been dosed.

The trial of BXQ-350, a novel anticancer therapeutic agent, will assess the effects of BXQ-350 on patients with advanced solid tumors.

"Dosing of our first ever patient with BXQ-350 is a significant milestone for Bexion," Bexion Founder and CEO Dr. Ray Takigiku said. "This trial is designed to study the safety and tolerability of BXQ-350 in patients with advanced solid tumors including glioblastoma multiforme (GBM) and may yield further insights into the potential anti-tumor activity of BXQ-350."

UCCI Phase I Experimental Therapeutics Program Director and UCCI faculty member Dr. John Morris will serve as the lead on the UCCI trial.

"We are very excited to be part of this groundbreaking trial which could change the way patients with solid tumors, like glioblastoma multiforme — a very aggressive type of brain cancer — are treated and possibly improve outcomes and their quality of life," Dr.mMorris said. "It's also a point of pride for UC and the UCCI that Dr. Xiaoyang Qi's original research work has led to a clinical trial that could ultimately help patients with solid tumors."